Cellular Therapy & Immunology, Manashi Chakrabarti Foundation, Kolkata.
Department of Blood & Marrow Transplantation, Dharamshila Narayana Superspeciality Hospital & Research Centre, New Delhi, India.
Immunotherapy. 2019 Oct;11(14):1221-1230. doi: 10.2217/imt-2019-0037. Epub 2019 Sep 3.
NK cell-based immunotherapy is one of the more exciting propositions in the field of cellular therapy for hematological malignancies. Current protocols are largely based on expanded and activated NK cells which are used both with and without allogeneic transplantation. Based on our recent findings, we discuss the concept of CTLA4Ig-primed donor lymphocyte infusions following haploidentical transplantation as an effective tool to garner NK cell-mediated antitumor effect with abrogation of T cell-mediated alloreactivity. This approach might widen the possibility of immunotherapy following haploidentical transplantation without increase in graft-versus-host disease. Further studies would be needed to establish the veracity of this concept with better understanding of the antitumor effect via this pathway. Future studies would decide if CTLA4Ig might be used to augment NK-cell activation as well.
基于自然杀伤（NK）细胞的免疫疗法是血液系统恶性肿瘤细胞疗法领域中令人振奋的治疗方法之一。目前的方案主要基于扩增和激活的 NK 细胞，这些细胞既可以用于异基因移植，也可以不用于异基因移植。基于我们最近的研究结果，我们讨论了 CTLA4Ig 预致敏供者淋巴细胞输注在单倍体相合移植后的概念，认为这是一种获得 NK 细胞介导的抗肿瘤效应、同时消除 T 细胞介导的同种异体反应性的有效工具。这种方法可能会扩大单倍体相合移植后免疫治疗的可能性，而不会增加移植物抗宿主病的风险。需要进一步的研究来确定这一概念的正确性，更好地了解通过这种途径的抗肿瘤效应。未来的研究将决定 CTLA4Ig 是否可用于增强 NK 细胞的激活。
